Browse All

Current Filters

CLEAR FILTER x

TITLE

Symptom Severity in Early-stage Relapsing Remitting Multiple Sclerosis

Author:Sainz de la Maza, Susana   Gómez-Ballesteros, Rocío   Borges, Mónica   Martín-Martínez, Jesús   Sotoca, Javier   Alonso, Ana   Caminero, Ana B   Borrega, Laura   Sánchez-Menoyo, José L   Barrero-Hernández, Francisco J   Calles, Carmen   Brieva, Luis   Blasco-Quílez, María R   Dotor Garcia-Soto, Julio   Campo-Amigo, María del   Navarro-Cantó, Laura   Agüera, Eduardo   Garcés-Redondo, Moisés   Carmona, Olga   Gabaldón-Torres, Laura   Forero, Lucía   Hervás, Mariona   Maurino, Jorge   Castillo-Trivino, Tamara   

Session Name:P5: MS Prognosis/Epidemiology  

Topic:MS and Inflammatory Disease  

Program Number:P5.009  

Author Institution:Hospital Universitario Ramón y Cajal, Madrid, Spain  Medical Department, Roche Farma, Madrid, Spain  Hospital Universitario Virgen Macarena, Sevilla, Spain  Hospital Universitario Miguel Servet, Zaragoza, Spain  Hospital Universitari Mútua Terrassa, Barcelona, Spain  Hospital Regional Universitario de Málaga, Málaga, Spain  Complejo Asistencial de Ávila, Ávila, Spain  Hospital Universitario Fundación Alcorcón, Madrid, Spain  Hospital de Galdakao-Usansolo, Galdakao, Spain  Hospital Universitario Clínico San Cecilio, Granada, Spain  Hospital Universitari Son Espases, Palma De Mallorca, Spain  Hospital Universitari Arnau de Vilanova, Lleida, Spain  Hospital Universitario Puerta de Hierro, Madrid, Spain  Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain  Hospital General Universitario de Elche, Elche, Spain  Hospital Universitario Reina Sofía, Córdoba, Spain  Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain  Fundació Salut Empordà, GIRONA, Spain  Hospital Francesc de Borja, Gandía, Spain  Hospital Universitario Puerta del Mar, Cádiz, Spain  Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain  Hospital Universitario Donostia, San Sebastian, Spain  

Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis

Author:Arnold, Douglas L.   Freeman, Leorah   Hartung, Hans-Peter   Montalbán, Xavier   Cohen, Jeffrey A.   Bar-Or, Amit   Steinman, Lawrence   DeLuca, John   Cheng, Chun-Yen   Riolo, Jon V.   Silva, Diego   Pachai, Chahin   Cree, Bruce A. C.   

Session Name:P5: MS Prognosis/Epidemiology  

Topic:MS and Inflammatory Disease  

Program Number:P5.010  

Author Institution:NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montréal, QC, Canada  Dell Medical School, The University of Texas at Austin, Austin, Texas, Austin, TX  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, Newark, NJ  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA